The sEH has been proposedas a therapeutic target in liver diseases, with therapeutic efficacyreported in NAFLD, liver fibrosis, and portal hypertension,779 potentially in combination with farnesoid Xreceptor (FXR) modulation.780 These findingscollectively suggest that dietary octadecanoids are involved withliver diseases and merit further investigation to their utility asmarkers of both chronic and acute diseases, and represent a potentialtreatment route via reduction in dietary LA. The gene discussed is EPHX2; the disease is liver disorder.